Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
New words:
Acacia, accompany, Addendum, audio, BioHub, biopharmaceutical, blocker, BTIG, Buena, cardiovascular, CareMax, charter, Comhear, Conexant, CZI, Depot, detection, discount, Disney, Exact, expertise, Forest, formatted, Gisela, GP, Gutfreund, Halle, hereof, hereto, Home, inclusion, Independa, Inline, John, Jr, Key, Lantronix, left, Letter, Li, mandatorily, Mankind, Maryland, multinational, Page, Paulsen, PC, pertained, Peter, pharmacy, PhD, platform, Political, Preferred, prohibited, read, recent, redeem, refiling, resource, Shortly, speak, Supply, Sweden, TV, type, updated, Uppsala, valuable, Vista, Wake, Walt, Withum, Wofford, Yu
Removed:
Bachelor, fourth, increased, Jumpstart, Mohanty, Schema, serve, Sr
Filing tables
Filing exhibits
Associated OCX transcripts
OCX similar filings
Filing view
External links
Exhibit 31.4
CERTIFICATIONS PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF
THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Mitchell Levine, certify that:
1. I have reviewed this Amendment No. 1 to Annual Report on Form 10-K/A of Oncocyte Corporation; and
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
Date: May 2, 2022
/s/ Mitchell Levine | |
Mitchell Levine | |
Chief Financial Officer |